Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications

• Published in: Current diabetes reports Vol. 21; no. 3; p. 8
• Main Authors: Martin, Katherine, Hatab, Anas, Athwal, Varinder S., Jokl, Elliot, Piper Hanley, Karen
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.03.2021; Springer Nature B.V
• Subjects: Diabetes; Genetic Predisposition to Disease; Genetics (AP Morris; Genetics (AP Morris, Section Editor); Humans; Liver; Liver diseases; Medicine; Medicine & Public Health; Non-alcoholic Fatty Liver Disease - genetics; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Section Editor; Topical Collection on Genetics; Genetic; Non-alcoholic fatty liver disease; Risk stratification
• ISSN: 1534-4827; 1539-0829; 1539-0829
• DOI: 10.1007/s11892-021-01377-5

Purpose of Review Non-alcoholic fatty liver disease (NAFLD) is a major and increasing health burden, with the potential to overwhelm hepatology services. However, only a minority of patients develop advanced liver disease. The challenge is early identification of patients at risk of progression. This review aims to summarize current knowledge on the genetic predisposition to NAFLD, and its implications for prognostication and risk stratification. Recent Findings PNPLA3 -I148M is the most robustly associated genetic variant with NAFLD. Recently, variants in TM6SF2 , MBOAT7 , GCKR and HSD17B13 have also been implicated. NAFLD is a complex disease, and any one genetic variant alone is insufficient for risk stratification, but combining multiple genetic variants with other parameters is a promising strategy. Summary It is anticipated that, in the near future, analysis of data from large-scale prospective cohorts will reveal NAFLD subtypes and enable the development of prognostic models. This will facilitate risk stratification of patients, enabling optimisation of resources to effectively manage the NAFLD epidemic.